Abstract
Suicide events and episodes are serious human psychiatric disorders affected by a great number of different environmental/economic factors, early trauma/abuse, human bad living habits, human genomic properties and drug intervention decisions. In order to improve antidepressant therapeutics in clinics, the relationships between efficacy and toxicities of antidepressants have to be considered fundamentally. Since the occurrences and risks of suicidal events or episodes come from interplay between insiders (chemical/genomic/bioinformatics factors) and outsiders (economic/social/ previous trauma conditions and so on), new perspectives and scientific studies must be implemented for revealing these interrelated factors step-by-step and updating therapeutics in human beings. New paradigms and clinical strategies –joint-expert groups and clinical practices (a psychiatrist with other field specialists) should be established for individual patients in future. Thus can some improvements in clinical trials be achieved in a long run?
Keywords: Economic conditions, environmental factors, human genome, medicinal chemistry, neural toxicity, Psychiatric disorders.
Central Nervous System Agents in Medicinal Chemistry
Title:The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary
Volume: 16 Issue: 3
Author(s): Da-Yong Lu, Peng-Peng Zhu, Ting-Ren Lu and Jin-Yu Che
Affiliation:
Keywords: Economic conditions, environmental factors, human genome, medicinal chemistry, neural toxicity, Psychiatric disorders.
Abstract: Suicide events and episodes are serious human psychiatric disorders affected by a great number of different environmental/economic factors, early trauma/abuse, human bad living habits, human genomic properties and drug intervention decisions. In order to improve antidepressant therapeutics in clinics, the relationships between efficacy and toxicities of antidepressants have to be considered fundamentally. Since the occurrences and risks of suicidal events or episodes come from interplay between insiders (chemical/genomic/bioinformatics factors) and outsiders (economic/social/ previous trauma conditions and so on), new perspectives and scientific studies must be implemented for revealing these interrelated factors step-by-step and updating therapeutics in human beings. New paradigms and clinical strategies –joint-expert groups and clinical practices (a psychiatrist with other field specialists) should be established for individual patients in future. Thus can some improvements in clinical trials be achieved in a long run?
Export Options
About this article
Cite this article as:
Lu Da-Yong, Zhu Peng-Peng, Lu Ting-Ren and Che Jin-Yu, The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1871524916666160210142734
DOI https://dx.doi.org/10.2174/1871524916666160210142734 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Mechanisms in Perinatal Hypoxic-Ischemic Brain Injury
Current Pediatric Reviews Current Status of Carbapenem Antibiotics
Current Topics in Medicinal Chemistry AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major
Cardiovascular & Hematological Disorders-Drug Targets Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Preclinical Drug Metabolism and Pharmacokinetics, and Prediction of Human Pharmacokinetics and Efficacious Dose of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237)
Drug Metabolism Letters Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Current Pharmaceutical Design Non-Alcoholic Fatty Liver Disease in Children
Current Nutrition & Food Science Vascular Arginase and Hypertension
Current Hypertension Reviews NADPH Oxidase and Neurodegeneration
Current Neuropharmacology Neurotrophins Role in Depression Neurobiology: A Review of Basic and Clinical Evidence
Current Neuropharmacology The Role of Dietary Polyphenols in the Management of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease
Current Molecular Pharmacology Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry Exploring Cancer Therapeutics with Natural Products from African Medicinal Plants, Part I: Xanthones, Quinones, Steroids, Coumarins, Phenolics and other Classes of Compounds
Anti-Cancer Agents in Medicinal Chemistry Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery